Switching From Wegovy to Mounjaro: UK Guide

Switching From Wegovy to Mounjaro: UK Guide

Date: 18 / Oct / 2026

Switching From Wegovy to Mounjaro: What You Need to Know

What to discuss with your prescriber before changing from semaglutide to tirzepatide.

Switching from Wegovy (semaglutide) to Mounjaro (tirzepatide) may be an option for some adults receiving prescription weight management treatment in the UK.

However, these medicines contain different active ingredients, and changing between them requires an individual assessment by an appropriately qualified prescriber.

This guide explains why a switch might be considered, how a treatment change is assessed, what the UK prescribing information says about starting doses, and what to know about side effects and clinical evidence.

Can You Switch From Wegovy to Mounjaro?

Yes. Some patients may be able to switch from Wegovy to Mounjaro if their prescriber considers the change appropriate.

Both are prescription-only medicines licensed for weight management in eligible adults, alongside a reduced-calorie diet and increased physical activity.

Wegovy contains semaglutide, which acts on the GLP-1 receptor. Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors.

Although both medicines affect appetite and weight regulation, they are not interchangeable.

Before recommending a change, your prescriber will consider your medical history, current medicines, treatment response, side effects and whether you meet the relevant prescribing criteria.

Do not stop, overlap or change your prescribed treatment without medical guidance.

Why Might Someone Switch?

A healthcare professional may discuss switching for several reasons:

  • Weight loss has slowed or plateaued. Your prescriber may review your progress and consider whether your current treatment remains appropriate.
  • Side effects are difficult to manage. Persistent or troublesome symptoms may lead to a review of your treatment.
  • A different treatment may be more suitable. Your medical history, other medicines and individual circumstances may affect the choice.
  • Treatment availability has changed. Supply issues may require a discussion about suitable alternatives.
  • Your treatment needs or goals have changed. Your prescriber may reassess your weight management plan.

A weight loss plateau does not automatically mean that a medicine has stopped working or that switching is necessary.

The decision should be based on your overall response to treatment, rather than weight changes alone.

How Does Switching From Wegovy to Mounjaro Work?

There is no single switching schedule that is appropriate for everyone.

Your prescriber will decide whether a change is suitable and explain how it should be managed.

This assessment may include:

  • Reviewing your current Wegovy dose and treatment history.
  • Considering how well you have tolerated semaglutide.
  • Deciding when your final Wegovy injection should be taken.
  • Advising when Mounjaro treatment should begin.
  • Selecting an appropriate starting dose in accordance with the prescribing information.
  • Reviewing other medicines or health conditions that could affect treatment.

Both medicines are administered by weekly injection, but this does not mean their doses or injection schedules can be directly exchanged.

Do not take both medicines together or calculate your own equivalent dose.

Do You Start Mounjaro on the Lowest Dose?

The UK prescribing information for Mounjaro specifies a starting dose of 2.5 mg once weekly, followed by an increase to 5 mg once weekly after four weeks.

Further increases, where appropriate, follow the licensed dose-escalation schedule.

Previous treatment with Wegovy does not establish an equivalent Mounjaro dose.

The gradual dose-escalation approach is intended to improve gastrointestinal tolerability.

Your prescriber will assess the appropriate treatment plan and explain how the licensed dosing instructions apply to your circumstances.

Do not assume that tolerating a higher dose of Wegovy means you can begin Mounjaro at a higher dose.

Will Side Effects Return After Switching?

Some people may experience digestive side effects when starting Mounjaro, even if they previously tolerated Wegovy.

Commonly reported effects include:

  • Nausea
  • Diarrhoea
  • Constipation
  • Vomiting
  • Abdominal discomfort
  • Reduced appetite

Digestive symptoms are often more noticeable when treatment begins or the dose increases. They may improve over time, although this is not guaranteed.

Persistent vomiting or diarrhoea can cause dehydration, which may lead to kidney problems.

Seek medical advice if symptoms are persistent, severe or prevent you from keeping fluids down.

Severe, persistent abdominal pain, particularly if it spreads to your back, requires urgent medical assessment because it may be a sign of pancreatitis.

Your prescriber should also review relevant precautions, including gallbladder problems, previous pancreatitis and other medicines.

If you use insulin or a sulphonylurea for diabetes, your prescriber may need to review your treatment because of the risk of low blood sugar.

Pregnancy and Contraception Considerations

Tell your prescriber if you are pregnant, planning a pregnancy or breastfeeding.

These medicines are not recommended during pregnancy, and the prescribing information includes specific advice about stopping treatment before a planned pregnancy.

Mounjaro may also reduce the effectiveness of oral hormonal contraception during treatment initiation and following dose increases.

The UK prescribing information advises people using oral hormonal contraception to consider switching to a non-oral method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase.

Your prescriber or pharmacist can explain how this guidance applies to you.

Is Mounjaro More Effective Than Wegovy?

Both Wegovy and Mounjaro have demonstrated weight loss benefits in clinical trials when used alongside dietary and physical activity measures.

The SURMOUNT-5 clinical trial directly compared tirzepatide and semaglutide in adults with obesity who did not have type 2 diabetes.

Over 72 weeks, participants receiving tirzepatide experienced greater average weight loss than those receiving semaglutide.

The trial compared tirzepatide at maximum tolerated doses of 10 mg or 15 mg with semaglutide at maximum tolerated doses of 1.7 mg or 2.4 mg.

SURMOUNT-5 did not compare tirzepatide with Wegovy 7.2 mg and was not a study specifically examining patients switching from one medicine to the other.

These findings describe average outcomes in a particular study population. They cannot predict how much weight an individual will lose after switching treatments.

A medicine that produces greater average weight loss in a clinical trial is not necessarily the most appropriate choice for every patient.

Your prescriber will consider potential benefits, side effects, medical history and treatment suitability.

Frequently Asked Questions

Can I Switch From Wegovy to Mounjaro Without a Consultation?

No. Changing between these prescription-only medicines requires assessment and guidance from an appropriately qualified prescriber.

Do I Need a Break Between Wegovy and Mounjaro?

The timing of a change should be determined by your prescriber.

Factors may include your most recent Wegovy injection, current dose, side effects, medical history and other medicines.

Do not choose a gap or overlap the medicines yourself.

Will I Lose More Weight After Switching to Mounjaro?

Not necessarily.

Although some clinical studies have reported greater average weight loss with tirzepatide than semaglutide, this does not establish how an individual will respond after switching.

Your progress will depend on several factors, including your response to treatment, nutrition, physical activity and treatment adherence.

Can I Use My Current Wegovy Dose to Calculate a Mounjaro Dose?

No. The medicines have different active ingredients and licensed dosing schedules.

There is no licensed milligram-for-milligram conversion table between semaglutide and tirzepatide.

Your prescriber must determine the appropriate treatment plan.

What If I Experienced Side Effects With Wegovy?

Tell your prescriber what symptoms you experienced, how severe they were and whether they have resolved.

Both medicines can cause gastrointestinal side effects. Changing treatment does not guarantee that these symptoms will disappear.

Can I Switch Back to Wegovy Later?

A further change may be considered if your prescriber determines that it is appropriate.

The decision would require a new assessment of your treatment history, tolerability and current circumstances.

You should not restart a previous medicine or dose without prescribing advice.

No Dose-Equivalence Shortcut

Wegovy and Mounjaro are different medicines, and their doses should not be treated as equivalent.

There is no licensed conversion table that allows patients to calculate a Mounjaro dose from their existing Wegovy dose.

A treatment change requires consideration of your medical history, current medicines, tolerability and the timing of your last injection.

Comparative clinical trials provide useful information about average treatment outcomes, but they do not establish a standard switching protocol or predict the outcome for an individual.

The key point is that switching should be a prescribing decision, not a self-directed dose conversion.

Sources and Scope

This article provides general educational information for UK adults considering a change between weekly injectable prescription medicines for weight management.

It does not cover treatment for other indications or other formulations.

The information should be read alongside the current patient information leaflet supplied with your medicine and advice from your prescribing healthcare professional.

Article updated: 18 October 2026.

Independent clinical review has not been completed.

References

  1. Mounjaro (tirzepatide) – UK Summary of Product Characteristics
  2. Wegovy (semaglutide) – UK Summary of Product Characteristics
  3. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity – New England Journal of Medicine, 2025
  4. MHRA – Report a Suspected Side Effect

Continue Reading

Explore more educational articles in the Slimming Direct Weight Management Guides, including information about treatment changes, side effects and prescription weight management medicines.


Medical Disclaimer

This article is provided by Slimming Direct for general educational purposes only.

It does not constitute personalised medical advice, diagnosis or treatment, and it should not be used as a substitute for consultation with an appropriately qualified healthcare professional.

Prescription weight management medicines should only be used under appropriate medical supervision. Do not start, stop, switch or change the dose of any prescribed medicine without advice from your prescriber.

Reporting side effects: Suspected adverse reactions can be reported through the MHRA Yellow Card Scheme.

Ready to Take the Next Step? Start Your Weight Loss Journey Today!

Take our short 5 minute questionnaire now.
Trustpilot